Moving Forward, a project made by the European Huntington Association

Find more information here

How to Navigate the Website

What people say about us

"Moving Forward is a fantastic project by the EHA that provides educational and emotional support to HD families! I am glad that I had the opportunity to be a part of its activities. It is an important step in connecting people affected by HD worldwide, in improving care, and in strengthening the HD community!"
« Fabulous Project »
Read the full post
« Very important project. You are doing your job very professionally, supporting and connecting people with HD in Europe, working together with researchers, neurologists, geneticists and other healthcare professionals, sharing information with HD families. »
Read the full article
« Excellent initiative from the European Huntington Association, with all kinds of information and contents »
Read the full post
« I had the pleasure of participating in one of the most spectacular HD events of my life thanks to the European Huntington Association »
Read the full post

Everything about HD

We have compiled reliable information to give you an overview of Huntington’s disease. You will find interesting, clear, and didactic links to articles, FAQ sheets, videos and audio files about the history, basics, and symptoms of HD. We believe that the better you understand HD, the better prepared you will be to deal with this diagnosis.


We have compiled information about past, ongoing and future HD clinical trials and studies. You will also find didactic contents about the basics of clinical trials and drug discovery pipeline. We believe that the more knowledgeable you are about the research process, the more proactive you will be in the collective effort to find effective disease-modifying treatments for HD.


We have compiled different sorts of information (articles, videos, podcast, online forum) to help HD families adjust to this diagnosis and get to know the HD global community. You will find valuable resources that provide psychological support, as well as practical tips to better cope with HD challenges. We believe that the more tools you have to help you face HD, the better quality of life and well-being you will achieve.

Uncomplicating HD Research: Mission Accomplished

– November 28th, 2022

On November 12th, in close collaboration with AVAEH – Asociación Valenciana de Enfermedad de Huntington and the Instituto de Investigación Sanitaria La Fe we were able to bring together a fantastic group of Spanish clinicians and researchers who are completely committed to providing the best care possible to HD families and to finding effective therapeutic options for those impacted by HD.

Read the full article here

Bookshelf - Open Books, Open Minds!

– November 10th, 2022

The Moving Forward team is happy to announce a new feature in the Moving Forward webpage, the Bookshelf. The team has compiled many interesting books of different genres, all of them related to Huntington’s Disease (HD). Here you can find a comprehensive list with a summary of each book and additional information about where to buy or read it online 📖

 🎯 Since one of the main goals of Moving Forward is to increase the health literacy and provide reliable information to the HD community, the project team thought it would be interesting to have a new section dedicated to all you book lovers out there.

Take a look at our international bookshelf

Moving Forward Poster Trilogy at the EHDN2022 Bologna Meeting

– October 18th, 2022

Filipa Júlio, the Moving Forward Project Manager, and Ruth Blanco, the Moving Forward Project Coordinator in Spain, attended the EHDN Plenary Meeting in Bologna last month. This was the first opportunity to present in-person the Moving Forward (MF) work to more than 1000 participants from all over the world who attended the largest and more important international HD conference.

Read the full article here

Prilenia Phase 3 Trial with Pridopidine – Why is it Different?

– September 13th, 2022

For all those who have been following Huntington’s disease research for some time, Pridopidine is an “old acquaintance”.

To date, several studies have been conducted with this drug, looking closely to its effect on dopamine. Although they have helped us to confirm the safety and good tolerability of pridopidine, none of these trials has been completely successful.

Read the full article here

UniQure: the Highs and Lows of AMT-130

– September 9th, 2022

UniQure is a company with an expertise in gene therapy that has long been involved in the search for HD treatment options. Their preclinical studies in animal models showed that AMT-130, the gene therapy product candidate for HD, reduced the mutant huntingtin protein and was associated with a decrease in the progression of Huntington’s disease signs.

Read the full article here

PIVOT-HD, PTC Therapeutics Phase 2 Trial to Lower Huntingtin

– September 8th, 2022

PTC Therapeutics is a US biopharmaceutical company specialized in the development of  gene therapies for rare diseases. The team at PTC Therapeutics has screened more than 300,000 molecules in the search for an effective therapeutical approach to HD, one  that can lower huntingtin, can be administered orally and can have an impact inside and outside of the brain. 

Read the full article here